TORONTO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today provided an update for its clinical development programs and milestones for 2023 with KETARX™ (racemic ketamine) as a potential treatment for mental health, neurological and pain disorders.
- Of the three forms of ketamine, only racemic ketamine and S-ketamine products have been approved by FDA.
- The Company recently completed the development of the microneedle patch system for the intradermal delivery of sustained low-dose ketamine.
- This milestone has enabled progression toward process validation and the manufacturing of cGMP clinical materials to support ongoing clinical development.
- Upon completion of the study, PharmaTher aims to seek guidance from the FDA to determine the final clinical development plan.